Literature DB >> 16491625

UGT1A1 genotyping in patients undergoing treatment with irinotecan.

Federico Innocenti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16491625

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.

Authors:  Luis Parodi; Eve Pickering; Laura A Cisar; Doug Lee; Raoudha Soufi-Mahjoubi
Journal:  Arch Drug Inf       Date:  2008-12

Review 2.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

3.  Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.

Authors:  Yingfang Fan; Najia Mansoor; Tasneem Ahmad; Rafeeq Alam Khan; Martin Czejka; Syed Sharib; Dong-Hua Yang; Mansoor Ahmed
Journal:  Oncotarget       Date:  2017-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.